Molecular therapy oncolytics

View the family homepage Submit Your Research.

Federal government websites often end in. The site is secure. Their timing was right on, as it was concurrent with the first FDA approval of an anti-PD-1 antibody, and the following year, we saw the first FDA approval of an oncolytic virus as a cancer therapy. Sadly, there has not yet been another oncolytic virus on the US market, though a few have received conditional approvals in other countries. No bacterial therapies have yet been approved, but there are numerous ongoing trials. Going by its title, MTO technically encompasses any therapy that destroys cancer onco, from the Greek onkos , meaning lump or mass; lysis, from the Greek lusis , meaning breaking down.

Molecular therapy oncolytics

Cell Press. How to publish in this journal. The set of journals have been ranked according to their SJR and divided into four equal groups, four quartiles. Q1 green comprises the quarter of the journals with the highest values, Q2 yellow the second highest values, Q3 orange the third highest values and Q4 red the lowest values. The SJR is a size-independent prestige indicator that ranks journals by their 'average prestige per article'. It is based on the idea that 'all citations are not created equal'. SJR is a measure of scientific influence of journals that accounts for both the number of citations received by a journal and the importance or prestige of the journals where such citations come from It measures the scientific influence of the average article in a journal, it expresses how central to the global scientific discussion an average article of the journal is. Evolution of the number of published documents. All types of documents are considered, including citable and non citable documents. This indicator counts the number of citations received by documents from a journal and divides them by the total number of documents published in that journal. The chart shows the evolution of the average number of times documents published in a journal in the past two, three and four years have been cited in the current year. Evolution of the total number of citations and journal's self-citations received by a journal's published documents during the three previous years.

How to publish in this journal.

.

Oncolytic viruses mediate antitumor responses through direct tumor cell lysis and induction of host antitumor immunity. However, the therapeutic efficacy of oncolytic viruses against malignant ascites has rarely been explored. This study aimed to evaluate the efficacy, safety, and immunomodulatory effect of an intraperitoneal injection of human type 5 recombinant adenovirus called H against malignant ascites. Forty patients with malignant ascites were recruited and treated with intraperitoneal H in the Fudan University Shanghai Cancer Center. The 4-week clinical responses were determined by an objective assessment of ascites volume change. Hmeditated tumor-specific immune activation on day 14 post-treatment was further identified by enzyme-linked immunospot assay. In conclusion, intraperitoneal H administration was well tolerated and effective in treating malignant ascites; thus, its immune activation ability may be a promising tool in combination with immunotherapy. Keywords: antitumor immune response; immunotherapy; malignant ascites; mass cytometry; oncolytic viruses. Abstract Oncolytic viruses mediate antitumor responses through direct tumor cell lysis and induction of host antitumor immunity.

Molecular therapy oncolytics

Application in antiviral discovery and disinfection procedures. Conventional cancer treatments have limited effectiveness in many cases. Oncolytic therapy, based on the use of armed viruses directed against tumor cells, offers new perspectives in the fight against this global scourge. Using autofluorescent viruses, we can measure the impact of the presence of a molecule of interest on virus infection and replication capacities. Our technology allows us to quickly calibrate and validate the development of disinfection devices. We can offer different types of imaging and also image analysis whether in a viral or non-viral context, from high content imaging to high resolution imaging and light sheet microscopy. Having the ability to directly visualize virus infection and replication in living cells using a breakthrough technology with minimum hands-on investment. This is what we propose at NeoVirTech. Our state of the art imaging and screening platform provides a rapid and powerful pipeline to discover compounds that will impact infection capacities and measure disinfection procedures on a large collection of viruses in the human and veterinary market. As our technology is image-based, the beauty and quality of the data generated is a tremendous asset to boost your research and expand your communication processes.

The sphere hunter face reveal

MTMCD focuses on advances in cell and gene therapy and how they are translated and applied in the clinical setting. International Collaboration accounts for the articles that have been produced by researchers from several countries. Documents Year Value Uncited documents 0 Uncited documents 2 Uncited documents 12 Uncited documents 10 Uncited documents 16 Uncited documents 12 Uncited documents 7 Uncited documents 17 Uncited documents 42 Cited documents 0 Cited documents 4 Cited documents 16 Cited documents 56 Cited documents 78 Cited documents 89 Cited documents Cited documents Cited documents Molecular Therapy. Here's how to claim your subscription:. No bacterial therapies have yet been approved, but there are numerous ongoing trials. Here's how to submit a request. Sadly, there has not yet been another oncolytic virus on the US market, though a few have received conditional approvals in other countries. How to publish in this journal. Desjardins A. Mol Ther Oncolytics. Navigate to the Membership Dashboard. It is based on the idea that 'all citations are not created equal'.

.

From bench to bedside: the history and progress of CAR T cell therapy. To serve the field best, Dr. This indicator counts the number of citations received by documents from a journal and divides them by the total number of documents published in that journal. Timothy P. Friedman G. Evolution of the number of total citation per document and external citation per document i. Published online Nov Here's how to claim your subscription:. MTO: a new journal for a maturing field. Furthermore, to provide expert management and review of a broader diversity of submissions, we plan to expand the expertise of our editorial board and our associate editors. Ethical Statements Read Molecular Therapy 's ethical statements on authorship, dual submission, competing interests, inclusion and diversity, and more. Molecular Therapy. The chart shows the evolution of the average number of times documents published in a journal in the past two, three and four years have been cited in the current year. Molecular Therapy Oncology MTO focuses on the development and testing of cancer therapies in pre-clinical and clinical settings, and provides a unique forum for work in the burgeoning fields of biologic cancer therapies including viral, bacterial, cellular, and gene therapy. All types of documents are considered, including citable and non citable documents.